Table 4.
Patient distribution according to anatomic-and pathologic prognostic stages and 5 & 10-year DFS & DSS rates.
| AJCC 8th Edition update Anatomic stage |
AJCC 8th Edition update Pathologic prognostic stage |
||||||
|---|---|---|---|---|---|---|---|
|
| |||||||
| n=289 | n=289 | ||||||
|
| |||||||
| Stage | n (%) | DFS | DSS | Stage | n (%) | DFS | DSS |
| IA | 90 (31.1) | 5-year 95.4% | 5-year 98.9% | IA | 108 (37.4) | 5-year 96.2% | 5-year 98.1% |
| 10-year 90.3% | 10-year 95.15 | 10-year 89.8% | 10-year 96% | ||||
|
| |||||||
| IB | 1 (0.3) | Lost to follow-up | Lost to follow-up | IB | 68 (23.5) | 5-year 93.8% | 5-year 98.4% |
| 10-year 88.8% | 10-year 91.5% | ||||||
|
| |||||||
| IIA | 77 (26.6) | 5-year 92% | 5-year 94.3% | IIA | 43 (14.9) | 5-year 81% | 5-year 90.4% |
| 10-year 85.6% | 10-year 91.1% | 10-year 70% | 10-year 77.3% | ||||
|
| |||||||
| IIB | 58 (20.1) | 5-year 85.9% | 5-year 92.9% | IIB | 32 (11.1) | 5-year 84% | 5-year 93.3% |
| 10-year 74.4% | 10-year 79.5% | 10-year 67% | 10-year 74.9% | ||||
|
| |||||||
| IIIA | 44 (15.2) | 5-year 72.2% | 5-year 90.6% | IIIA | 21 (7.3) | 5-year 45.1% | 5-year 90% |
| 10-year 69.6% | 10-year 69.9% | 10-year 45.1% | 10-year 47.6% | ||||
|
| |||||||
| IIIB | 2 (0.7) | No recurrence | Alive | IIIB | 9 (3.1) | 5-year 50% | 5-year 62.5% |
| 10-year 50% | 10-year 50% | ||||||
|
| |||||||
| IIIC | 17 (5.9) | 5-year 43.1% | 5-year 71.4% | IIIC | 8 (2.8) | 5-year 71% | 5-year 71% |
| 10-year 43.1% | 10-year 41.7% | 10-year 71% | 10-year 71% | ||||
DFS – disease free survival; DSS – disease specific survival.